Integrated Partnership With PharmaPros Dataflow Manager Enables New Functionality
FORT LAUDERDALE, Fla., June 25, 2012 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCBB:OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced a new level of integration with PharmaPros that provides OmniComm customers with a solution offering next-generation CTMS capabilities for mid-sized organizations interested in a flexible, SaaS solution for clinical trials management. This new integrated solution provides capabilities for Site Management & Monitoring, Budget Tracking & Management, eTMF/Document Tracking, Metrics Portal & Real-time Reporting.
With access to these new tools, OmniComm customers can manage their clinical trial information in a more automated and scalable way. Connecting Trial Master EDC directly to Dataflow Manager through the OmniConnect web-based API eliminates the administrative burden of redundant data entry and reconciliation for clinical Sponsor and CRO organizations across a wide range of eClinical products, reducing trial costs, and providing significant workflow efficiencies.
"We are extremely pleased that OmniComm is now bundling Dataflow Manager's unique study management capabilities with their TrialMaster EDC product," said Brion Regan, Head of Strategic Development, PharmaPros. "We've already seen the benefits within our shared customer base, and have been impressed. OmniComm has proven to be a strong technology partner, with the ability to rapidly address the needs of their customers with value-driven solutions."
This integrated partnership enables OmniComm customers to add Dataflow Manager to their TrialMaster solution on an as-needed or per-trial basis. This flexibility gives customers the ability to quickly scale up or down, based on the needs of the trial, without costly and time-consuming implementations required by traditional CTMS solutions.
"We are excited about this new partnership and the benefits this marriage of EDC and CTMS will provide to our customers," said Stephen Johnson, President and COO of OmniComm. "This integrated partnership and solution is just one more example of how OmniComm is continuing to help our customers connect data across the eClinical spectrum."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.